This bill mandates that health care providers enrolled in NJ FamilyCare, who are licensed to prescribe psychotropic drugs, must provide specific information to the parent or guardian of a child before prescribing an antipsychotic medication. The required information includes the FDA-approved Medication Guide for the drug, details on evidence-based alternatives for treatment, and guidance on accessing the FDA's Adverse Event Reporting System and MedWatch tools. Additionally, providers must obtain a signed consent form from the parent or guardian, confirming their understanding of the drug's potential risks, awareness of alternatives, and knowledge of reporting tools for adverse effects. This signed consent must be retained in the child's patient file.

The bill defines a "child" as any individual aged 18 or younger enrolled in NJ FamilyCare, which encompasses both Medicaid and the Children's Health Insurance Program. It also outlines the responsibilities of the Commissioner of Human Services to apply for necessary state plan amendments or waivers to implement the bill and secure federal funding, as well as to adopt any required rules and regulations under the Administrative Procedure Act. The act is set to take effect three months after its enactment, although anticipatory administrative actions may be taken beforehand for implementation.